2-氰基-[1,1-联苯]-4-羧酸甲酯 | 89900-98-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氰基-[1,1-联苯]-4-羧酸甲酯
• 英文名称: methyl 2'-cyano-[1,1'-biphenyl]-4-carboxylate
• 英文别名: methyl 4-(2-cyanophenyl)benzoate；methyl 4-(2-cyanophenyl)-benzoate
• CAS: 89900-98-1
• 化学式: C₁₅H₁₁NO₂
• 分子量: 237.258
• InChiKey: ZSTFCQLEIZCGLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 4-(2-cyanophenyl)benzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 4-(2-cyanophenyl)benzoate
CAS number: 89900-98-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H11NO2
Molecular weight: 237.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氰基-[1,1-联苯]-4-羧酸甲酯 在 水 作用下， 以 甲醇 为溶剂， 生成 2-氰基-[1,1-联苯]-4-羧酸
  参考文献：
  名称：

  Ananthakrishnanadar, Ponnambalanad.; Kannan, Nagarathnam, Journal of the Chemical Society. Perkin transactions II, 1984, # 1, p. 35 - 38

  摘要：

  DOI：
• 作为产物：
  描述：

  邻氯苯腈 、 4-carbomethoxyphenyl triflate 在 nickel(II) chloride2-methoxyethyl ether 、 1,4-双(二苯基膦)丁烷 、 4,4'-二叔丁基-2,2'-二吡啶 、 lithium chloride 、 palladium dichloride 、 锌 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以61%的产率得到2-氰基-[1,1-联苯]-4-羧酸甲酯
  参考文献：
  名称：

  LiCl 加速芳基氯与芳基三氟甲磺酸酯的多金属交叉偶联

  摘要：

  尽管联芳基化合物的合成在过去几十年中取得了迅速进展，但最丰富的芳基亲电试剂——芳基氯的交叉乌尔曼偶联仍然难以捉摸。这里报道了芳基氯与芳基三氟甲磺酸酯的第一个通用交叉乌尔曼偶联反应。使用多金属策略和适当选择的添加剂可以克服与惰性亲电试剂与反应性亲电试剂偶联相关的选择性挑战。研究表明，LiCl 通过加速 Ni(II) 还原为 Ni(0) 并抵消 Zn(II) 盐对 Zn(0) 还原的自抑制，对于有效交叉偶联至关重要。修改后的条件可耐受任一偶联配偶体上的各种官能团（42 个示例），示例包括氟比洛芬的三步合成。

  DOI：

  10.1021/jacs.9b05461

文献信息

• Integration of borylation of aryllithiums and Suzuki–Miyaura coupling using monolithic Pd catalyst
  作者：A. Nagaki、K. Hirose、Y. Moriwaki、K. Mitamura、K. Matsukawa、N. Ishizuka、J. Yoshida

  DOI：10.1039/c5cy02098k

  日期：——

  Integration of the preparation of arylboronic esters via aryllithiums and Suzuki–Miyaura coupling using monolithic Pd catalyst without an intentionally added base was achieved. A continuous operation has been done successfully for over 21 hours.

  通过使用整体式Pd催化剂而无需有意添加碱的情况下，通过芳基锂和Suzuki-Miyaura偶联制备芳基硼酸酯的过程得以实现。连续操作已成功完成21个小时以上。
• Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
  申请人：——

  公开号：US20030065176A1

  公开（公告）日：2003-04-03

  The present invention relates to a compound with aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amindonoaryl-alanines, represented by formula (1), a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate or an isomer thereof, which are inhibitors of coagulation enzyme, factor Xa (FXa). The present invention also relates to a pharmaceutical composition containing the compound, and a method of using the same as an anticoagulant agent for treatment and prevention of thrombosis disorders.

  本发明涉及一种具有芳基胺基的化合物，特别是表示为式（1）的芳基胺基环丙烷，芳基胺基甲基吡咯烷，芳基胺基苯，芳基胺基吡啶或芳基胺基丙氨酸的化合物，其为凝血酶Xa（FXa）的抑制剂，包括药用盐、前药、水合物、溶剂合物或其异构体。本发明还涉及含有该化合物的药物组合物，以及将其用作抗凝血剂治疗和预防血栓症障碍的方法。
• BICYCLIC HETEROCYCLIC COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20140249151A1

  公开（公告）日：2014-09-04

  [Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating 11β-hydroxysteroid dehydrogenase type 1-related diseases such as dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance and the like. [Means for Solution] A bicyclic heterocyclic compound (the bicyclic heterocycle is formed when a cyclohexane ring is fused with a 5- to 6-membered monocyclic heterocycle that has only a nitrogen atom as a hetero atom) substituted with an acylamino group such as a (hetero)aroylamino group or the like or a pharmaceutically acceptable salt thereof was found to have an excellent selective inhibitory action against 11β-HSD1. Accordingly, the bicyclic heterocyclic compound of the present invention can be used for treating dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance, and the like.

  提供一种化合物，作为药物组合物的有效成分，用于治疗与11β-羟基类固醇脱氢酶1相关的疾病，如痴呆症、精神分裂症、抑郁症、疼痛（尤其是神经病性疼痛或纤维肌痛）、糖尿病（尤其是2型糖尿病）、胰岛素抵抗等。解决方法是发现一种带有酰胺基（如（杂）芳酰胺基等）或其药用可接受盐的取代的双环杂环化合物（当环己烷环与仅有氮原子作为杂原子的5-至6-成员单环杂环融合时形成双环杂环化合物），发现其对11β-HSD1具有出色的选择性抑制作用。因此，本发明的双环杂环化合物可用于治疗痴呆症、精神分裂症、抑郁症、疼痛（尤其是神经病性疼痛或纤维肌痛）、糖尿病（尤其是2型糖尿病）、胰岛素抵抗等。
• Biaryl substituted imidazole compounds useful as farnesyl-protein
  申请人：Merck & Co., Inc.

  公开号：US06080870A1

  公开（公告）日：2000-06-27

  The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

  本发明涉及抑制法尼醇蛋白转移酶（FTase）和致癌基因蛋白Ras的法尼基化的化合物。本发明还涉及包含本发明化合物的化疗组合物以及抑制法尼醇蛋白转移酶和致癌基因蛋白Ras的方法。
• Palladium-Catalyzed para-Selective C–H Olefination and Acetoxylation of Benzylamines Enabled by an Unmasked Benzoyl Template
  作者：Jinghong Tang、Jun Huang、Guoshuai Li、Zelin Liu、Siquan He、Zhong Jin

  DOI：10.1021/acs.orglett.4c01785

  日期：2024.7.26

  activation, remote para-selective C–H functionalization of benzylamines has hitherto not been realized to date. Here, we report a palladium-catalyzed para-selective C–H olefination and acetoxylation of benzylamines using a functionalized benzoyl template. Enhancing the coordination strength of the directing group in the template significantly improved the site selectivity of C–H functionalization.

  苄胺属于生物活性天然产物和药物合成中的一类重要结构单元。由于酰胺定向的邻位-C-H激活，苄胺的远程对位选择性C-H官能化迄今为止尚未实现。在这里，我们报道了使用功能化苯甲酰基模板的钯催化对位选择性 C-H 烯化和苯甲胺的乙酰氧基化。增强模板中导向基团的配位强度显着提高了C-H官能化的位点选择性。